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Edited by Christian GriesingerAbstract The cyclotides are a family of head-to-tail cyclized
peptides that display exceptionally high stability and a range of
biological activities. Acyclic permutants that contain a break in
the circular backbone have been reported to be devoid of the
haemolytic activity of the prototypic cyclotide kalata B1, but the
potential role of the charges at the introduced termini in this loss
of membraneolytic activity has not been fully determined. In this
study, acyclic permutants of kalata B1 with capped N- and C-
termini were synthesized and found to adopt a native fold. These
variants were observed to cause no measurable lysis of erythro-
cytes, strengthening the connection between backbone cycliza-
tion and haemolytic activity.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Amidation1. Introduction
The cyclotides are a fascinating family of plant-derived pep-
tides characterized by their knotted arrangement of three di-
sulﬁde bonds and head-to-tail cyclization [1]. They possess a
wide array of biological activities but their natural function in
plants appears to be as defence molecules [2]. More than 50
members of the family are currently known and their rate of
discovery has increased in recent years [3–5]. The ﬁrst cyclotide
to be structurally characterized, kalata B1 (KB1) [6,7], is the
most thoroughly studied peptide in this family. Fig. 1 shows a
schematic representation of the macrocyclic backbone and
cystine knot [8,9], and indicates the nomenclature for deﬁning
the six backbone loops between the cysteine residues.
Some members of this family possess moderate haemolytic
activity, with EC50 values in the 30–1500 lM range [10–13].
The mechanism for haemolysis is unknown, but it has been
suggested that it is related to cell membrane disruption based
on the hydrophobic nature of these peptides [12]. The ex-
tremely high stability of the cyclotides suggests that they might
make useful scaﬀolds for bearing bioactive peptide epitopes in
order to improve stability and bioavailability for pharmaceu-
tical applications [14]. Therefore, understanding the basis for
undesirable activities such as haemolytic activity is essential to
their successful utilization.
The haemolytic activity appears to be linked to the cyclic
backbone based on a study of synthetic derivatives where a* Corresponding author. Fax +61-7-3346-2029.
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Several acyclic permutants of the prototypic cyclotide kalata B1
were demonstrated to have lost all haemolytic activity despite
havingnative global folds [10].However, the precise relationship
between cyclization andhaemolytic activity is not clear from this
single study. The introduction of free termini into acyclic per-
mutants adds charges to the peptides at physiological pH, ren-
dering signiﬁcant diﬀerences in the electrostatic proﬁle of their
surfaces relative to the native cyclic peptides. This is especially
relevant if their hydrophobic nature is essential to their activity.
Although earlier acyclic permutants with C-terminal amides
have been synthesized and found to lack haemolytic activity [10],
the eﬀects of introducing N-terminal positive charges have not
been investigated.
To address these issues, a series of acyclic permutants of
kalata B1 were synthesized with capped amino and carboxyl
termini to mask the introduced charges. In particular, combi-
nations of N-terminal acetylation and C-terminal amidation
were synthesized as shown in Fig. 1. The folding and activity of
these peptides were assessed to gain a more detailed under-
standing of the relationship between backbone cyclization and
haemolytic activity.2. Materials and methods
2.1. Synthesis
Capped acyclic permutants of kalata B1 were assembled using
manual solid phase peptide synthesis with Boc chemistry. Compounds
with a free C-terminus (N-KB1-C, Ac-KB1-C) were synthesized on a
0.35 mmol scale using Pam-Asn resin. The resin was split in half for the
ﬁnal N-terminal acetylation of Ac-KB1-C with acetic anhydride/pyri-
dine. Compounds with an amidated C-terminus (N-KB1-Am, Ac-
KB1-Am and Ac-[des-Gly]-KB1-Am) were synthesized on a 0.5 mmol
scale. The resin was split into thirds after the coupling of the penul-
timate leucine. One third was acetylated to give Ac-[des-Gly]-KB1-Am,
one third was coupled to glycine to give N-KB1-Am and one third was
coupled to glycine then acetylated to give Ac-KB1-Am.
Cleavage of the peptides from the resin was conducted using hydrogen
ﬂuoride in the presence of p-cresol and p-thiocresol (18:1:1 v/v). The
reaction proceeded at 0 C for 90 min. The peptides were then dissolved
in 50% acetonitrile/0.05% TFA and lyophilized. The crude reduced
peptides were puriﬁed using preparative RP-HPLC on a Vydac C-18
column.Gradients of 1%perminuteof 90%acetonitrile/10%H2O/0.05%
TFA against 0.05% TFA/H2O at a ﬂow rate of 8 ml/min were employed
and the eluant proﬁle was monitored at 230 nm. Similar conditions were
used for subsequent puriﬁcations. Mass analysis was performed on a
Sciex triple quadrupole mass spectrometer (Thornhill, Ontario) using
electrospray ionization.
Oxidation of the peptides was achieved by dissolving the puriﬁed
reduced peptides in 2-propanol and 0.1 M ammonium bicarbonate
(pH 8.0) (50:50 v/v) with 10 mM glutathione and stirring at room
temperature overnight. The solutions were acidiﬁed with TFA and the
isopropanol removed under vacuum before RP-HPLC. Final peptideation of European Biochemical Societies.
Fig. 1. Schematic representation of the cyclotide framework and sequences of kalata B1 and capped acyclic permutants. The backbone is shown in
black ribbon and the disulﬁde bonds in grey shading, Cysteine residues are indicated with Roman numerals. The sequences of various acyclic
permutants are shown in one-letter amino acid codes. Capping functionalities are indicated in bold on the sequences. In the compound names, N
refers to a free amino terminus, C to a free carboxyl, Ac to an N terminal acetyl and Am to a C terminal amidation. The numbering of backbone
loops between the cysteine residues is indicated in the schematic diagram and above the tabulated sequences.
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(oxidized as crude to mitigate low solubility/3), N-KB1-Am (15/3), Ac-
KB1-Am (10/0-the peptide was lost during HPLC due to low solu-
bility) and Am-[des-Gly]-KB1-Ac (11/2).
2.2. NMR spectroscopy
Samples for 1D 1H NMRmeasurements contained 1 mg peptide in
120 ll of 10% D2O/H2O at pH 7. Spectra were recorded at 290 K on a
Bruker DMX-750 MHz spectrometer equipped with a shielded gra-
dient unit using a 2.5 mM probe. A sample of Am-[des-Gly]-KB1-Ac
for 2D 1H NMR was dissolved in 500 ll of 10% D2O/H2O at pH 4,
and NOESY and TOCSY spectra were acquired on a Bruker-AMX
600 MHz spectrometer at 290 K. The spectra were assigned using the
standard sequential assignment strategy to derive 1H chemical shifts
for all residues [15]. D2O was obtained from Cambridge Isotope
Laboratories, Woburn, MA. Spectra were processed on a Silicon
Graphics Indigo workstation using XWINNMR (Bruker) software.
2.3. Haemolytic activity assays
Sheep erythrocytes were washed six times with a 10-fold excess of
PBS by serial centrifugation at 4000 rpm, then a 1% (v/v) solution of
red blood cells in PBS was prepared. Test peptides were added to 20 ll
of 1% red blood cell solution to make a total sample volume of 100 ll
and ﬁnal peptide concentrations of 50, 100 and 200 lM. The samples
were incubated for one hour at room temperature, centrifuged and the
absorbance at 415 nm of 20 ll of supernatant in 600 ll water was
measured. Controls of 1% SDS for complete haemolysis and PBS for
zero haemolysis were run concurrently.
3. Results
Synthesis of the capped acyclic permutants presented some
minor diﬃculties. The yields of the compounds with a free C-terminus were reduced by the formation of a C-terminal suc-
cinimide of Asn during HF cleavage. This was ameliorated by
ensuring that the reaction was kept below 0 C and not al-
lowed to proceed for more than 90 min. Two of the variants
with N-terminal acetylation (Ac-KB1-C and Ac-KB1-Am) had
low solubility in the reduced and oxidized forms that was
manifest as an incompatibility with ultraﬁltration membranes
and HPLC guard columns, causing them to rapidly clog. This
occurred even at high dilutions when there was no visible
precipitate and led to the loss of Ac-KB1-Am during HPLC.
Consequently, the oxidization of Ac-KB1-N was done in an
unpuriﬁed state and ﬁnal puriﬁcation was done without ul-
traﬁltration. A third acetylated analogue, Ac-[des-Gly]-KB1-
Am, that was lacking the N-terminal glycine residue was also
prepared and displayed normal solubility. Despite the diﬃ-
culties, the ﬁnal yields of puriﬁed, oxidized peptides were
suﬃcient to allow NMR analysis and haemolytic assays for the
remaining peptides. Oxidation trial proﬁles for the acyclic
permutants were similar to those previously observed for na-
tive cyclotides, showing a characteristic increase in retention
time upon forming the native oxidized fold [10].
NMR spectroscopy of the peptides indicated that they were
correctly folded. Fig. 2 shows partial 1D 1H NMR spectra of
the native peptide and capped acyclic variants at pH 7, with
each showing similar amide ﬁngerprint regions and a charac-
teristic upﬁeld proline b-proton shift ()0.25 ppm [7]). The
sparsity of peaks in the amide region of the variants is due to
rapid amide exchange at this pH resulting in a loss of some
Fig. 2. 1H NMR spectra of selected regions of native and acyclic an-
alogues of kalata B1.
Fig. 4. Haemolytic activity for cyclic kalata B1 (solid line) and acyclic
derivatives (dashed lines); , N-KB1-C; n, Ac-KB1-C; , N-KB1-Am
and s, Ac-[des-Gly]-KB1-Am.
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intramolecular hydrogen bonds visible. Further analysis of Ac-
[des-Gly]-KB1-Am at lower pH showed that the aH chemical
shifts were consistent with the peptide adopting the same
global fold as native cyclic KB1. The diﬀerences in aH chem-
ical shifts of the acyclic permutant Ac-[des-Gly]-KB1-Am rel-
ative to the native cyclic KB1 are summarized in Fig. 3. The
chemical shifts in loop 6 diﬀer from those in the native peptide
due to the introduced break in the backbone, but the shifts are
closely comparable between the two peptides for the rest of the
molecules.Fig. 3. aH Chemical shift diﬀerences between Ac-[des-Gly]-KB1-Am
and kalata B1 at pH 4. White bars correlate with white regions on the
inset schematic and indicate structurally perturbed residues.Haemolytic assays showed a concentration dependent
erythrocyte lysis for the wild-type cyclic kalata B1, as sum-
marized in Fig. 4. Sheep blood was found to be more resilient
than human blood [11], with a maximum of 14% haemolysis
observed at 200 lM peptide concentration. In contrast with
the wild type peptide, all acyclic permutants had no observable
haemolytic activity up to 200 lM.4. Discussion
In this study, we have explored the connection between cy-
clization, terminal charges and loss of haemolytic activity in
the prototypic cyclotide kalata B1. Capped acyclic analogues
of kalata B1 were synthesized and shown to adopt essentially
the same fold as the native cyclic peptide but they displayed no
haemolytic activity, in contrast to the native peptide.
Acyclic permutants of kalata B1 in which the C- and N-
terminal charges were eliminated underwent oxidation in a
manner similar to previously prepared linear and cyclic ana-
logues. Unusual solution properties of two N-terminally
acetylated variants were observed. Their reduced and oxidized
forms were incompatible with microﬁltration, even when in an
apparently soluble state. The capped acyclic analogue Ac-[des-
Gly]-KB1-Am was considered to be a suitable replacement for
the Ac-KB1-Am that was lost due to its unusual solution
properties. The observation that Ac-[des-Gly]-KB1-Am had
more favourable solution properties than the other acetylated
permutants is noteworthy. In this compound the N terminal
Gly was omitted, allowing the N terminal acetyl group to ﬁll
the space normally occupied by this amino acid. This com-
pound represents an acyclic mimic of kalata B1 with the
smallest possible steric and electrostatic modiﬁcation, being in
eﬀect a version of the wild-type peptide where the only mod-
iﬁcation is the hydrogenation of the N-Ca bond of the glycine
in loop 6, as indicated in Fig. 5. The diﬃculties experienced
with the two full-length acetylated analogues suggest that the
acetyl group introduces a signiﬁcant steric clash.
NMR analysis of the peptides clearly indicated that they
adopt a global fold comparable to the native cyclic peptide. An
analysis of the chemical shifts of the acyclic mimic Ac-[des-Gly]-
KB1-Am, as shown in Fig. 3, indicated only minor aH chemical
shift variations relative to the native peptide in the majority of
the sequence. As expected, those residues closest to the intro-
duced termini were more highly disrupted. Inspection of the
Fig. 5. Chemical structures of break region of loop 6 of kalata B1 and
acyclic analogue Ac-[des-Gly]-KB1-Am, illustrating the isosteric na-
ture of the analogue compared to the native peptide.
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region of the backbone is involved in a hydrogen bond between
residues 24 and 27. Cleavage of the backbone at this position
will clearly disrupt this hydrogen bond and destabilize the loop.
Similar results were seen in a previously studied acyclic per-
mutant of loop 6 with a free N-terminus [10]. This reinforces the
suggestion that a cyclic backbone is not essential for the for-
mation of the native global fold and further establishes that
terminal charges are also not essential for folding. Although
native-like structures are generally maintained, the spectra
show some subtle diﬀerences in the acyclic permutants com-
pared to the cyclic peptide. In particular, the paucity of amide
peaks in spectra measured on the acyclic permutants at pH 7
indicated that as expected, many amide protons undergo sig-
niﬁcant exchange at this pH. The retention of a larger number
of amide protons at this pH in the wild type peptide [16] suggests
that the intramolecular hydrogen bond network observed in the
native is not fully maintained in the analogues. This is consistent
with earlier observations that acyclic permutants of kalata B1
displayed enhanced amide exchange rates, relative to the native
cyclic peptide, at pH 4 for the majority of amide protons in the
b-sheet region C15-V29 [10].
The activity of wild-type kalata B1 on sheep erythrocytes
was observed to be signiﬁcantly weaker than previous obser-
vations on human blood, with an EC50 > 1 mM compared to as
potent as 30 lM for human erythrocytes. This is consistent
with prior observations of the sensitivity of haemolytic assays
to variations in the nature of the blood used [10]. In contrast
with the native peptide, the acyclic permutants were found to
have no observable haemolytic activity at the concentrations
used here, as shown in Fig. 4. Masking of the C-terminal
carboxylic acid or the N-terminal amine did not reintroduce
haemolytic activity. In addition, the preparation of a com-pound with eﬀectively only hydrogenation of the N-C bond
gave a comparable result. This shows that the introduction of
terminal charges is not responsible for the loss of haemolytic
activity in acyclic permutants of kalata B1 and establishes a
clear link between backbone cyclization and haemolysis. The
possibility exists though that a capped acyclic permutant of
another loop may retain some haemolytic activity. However,
this seems inconsistent with the emerging pattern of delocal-
ized activity dependent on structural stability.
Although this study strengthens the connection between
backbone cyclization and haemolytic activity, the prospective
use of the cyclotide framework as a scaﬀold for carrying bio-
active peptide epitopes still remains promising. This work has
demonstrated that haemolytic activity is perturbed by minor
modiﬁcations to the molecule, suggesting that changing amino
acid side chains without breaking the cyclic backbone or
compromising the stability of the framework should be capa-
ble of reducing haemolytic activity to acceptable levels.
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